Sort
82,697 grants matching “vaccine development”
Development of NHP Models for Infectious Pathogens of Man
$975,224Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Peripheral Tissue Biomarker for Premorten Diagnosis of Lewy Body Dementia
$975,214Shu G Chen · Case Western Reserve University · R01 · FY2021 · NS
Product optimization to commercialize an oral bacteriophage cocktail that prevents cholera in real-world settings
$975,187Minmin Yen · Phagepro, Inc. · R44 · FY2022 · AI
Avian Flu A/H5N1 Vaccine Development in Vietnam
$975,000Nguyen Van Thu · Company For Vaccine & Biol Prodtn No, 1 · U01 · FY2006 · CI
Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma
$974,959Yen Tun Wang · Curebiotech, Inc. · R44 · FY2020 · CA
Preclinical evaluation of a trivalent Marburg vaccine
$974,845John Y Dong · Genphar, Inc. · U01 · FY2006 · AI
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
$974,750Chinnaswamy Jagannath · Methodist Hospital Research Institute · R01 · FY2021 · AI
Immune reconstitution following autologous and allogeneic stem cell transplant
$974,472Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA
COBRE Center for Molecular and Tumor Virology
$974,442Dennis John O'Callaghan · Louisiana State Univ Hsc Shreveport · P30 · FY2014 · GM
Molecular Biomarkers for Malaria
$974,388Dyann F Wirth · Harvard School Of Public Health · R56 · FY2009 · AI
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
$974,351Jake Reder · Celdara Medical, Llc · R44 · FY2022 · AI
EARLY AND REINFECTION IN HIGH RISK WOMEN
$974,201Julie M Overbaugh · Fred Hutchinson Cancer Research Center · R37 · FY2011 · AI
Multiplexed Antigen-Specific Antibody Fc Profiling on a Chip for Point-of-Care Diagnosis of TB in HIV-infected Children
$974,009Galit Alter · Massachusetts General Hospital · R01 · FY2020 · AI
PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization
$974,007Stephen Lev Hoffman · Sanaria, Inc. · SB1 · FY2022 · AI
Molecular Approaches To Antiviral and Vaccine Development For Hepatitis C
$973,984T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK
Optimizing Antibody Vaccines Against HIV
$973,960William Schief · Massachusetts General Hospital · P01 · FY2015 · AI
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect
$973,936Wolfgang W Scholz · Mabvax Therapeutics, Inc. · R44 · FY2011 · CA
NIDA Clinical Trials Network: Greater New York Node
$973,826John P Rotrosen · New York University School Of Medicine · UG1 · FY2019 · DA
Scanning Chlamydia proteome for vaccine antigens
$973,681Luis M De La Maza · Immport Therapeutics, Inc. · R42 · FY2009 · AI
Pediatric AIDS Clinical Trials Group
$973,663University Of California San Diego · U01 · FY2004 · AI
Preclinical Development of Full Length Single Chain
$973,622Timothy R Fouts · Profectus Biosciences, Inc. · R44 · FY2012 · AI
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection
$973,438Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · AI
An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease
$973,438Eileen M. Barry · University Of Maryland Baltimore · U19 · FY2023 · AI
Autoimmunity: Mechanisms of Unresponsiveness
$973,295Stanford University · P01 · FY2004 · AI
Development
$973,238Ana M Navarro · University Of California, San Diego · U54 · FY2009 · CA